Search results
Showing 1066 to 1080 of 1285 results for social care
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development Reference number: GID-TA10886 Expected publication date: TBC
Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711
Workplace health for employees with disabilities and long-term conditions
Discontinued Reference number: GID-PHG58
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]
In development Reference number: GID-TA11640 Expected publication date: TBC
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
Discontinued Reference number: GID-MT517
Discontinued Reference number: GID-PHG0
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
In development Reference number: GID-TA11352 Expected publication date: TBC
Discontinued Reference number: GID-TA10277
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.